UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report
(Date of earliest event reported)
August 10, 2011
Inovio Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
|
| Delaware
|
|
001-14888
|
|
33-0969592 |
| |
|
|
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.) |
| |
|
|
|
1787 Sentry Parkway West
Building 18, Suite 400
Blue Bell, Pennsylvania
|
|
19422 |
|
|
|
|
| (Address of principal executive offices)
|
|
(Zip Code) |
Registrant’s telephone number, including area code: (267) 440-4200
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal
Year.
On August 10, 2011, our board of directors approved our amended and restated bylaws. We
amended our bylaws to change the designation of our chairman of the board from an executive officer
position to a non-officer board position, unless our board of directors expressly designates our
chairman of the board as an officer.
Item 9.01. Financial Statements and Exhibits.
| |
|
|
| Exhibit No. |
|
Description |
3.2
|
|
Amended and Restated Bylaws of Inovio Pharmaceuticals, Inc.
dated as of August 10, 2011. |